DxPG80 IVD Test

DxPG80 does only one thing:

detect and measure hPG80

in human plasma

 

But it is the only test that provides physicians with new, highly accurate, reliable, reproducible and cost-effective information on the presence of hPG80 in their patients' blood.

DxPG80 IVD test is CE marqued under the project name cancerREAD. Regulatory revisions are ongoing.

SIMPLE

RELIABLE

REPRODUCTIBLE

AFFORDABLE

One tool: two applications

1. > Help  Cancer Susceptibility detection

THE GOAL

DxPG80.smart is a new tool to help detect various types of cancer at an early stage. Confirm diagnostic and screening tests.

 Cancer 

Susceptibility  detection

APPROACH

  • Aid to confirm current tests and for early cancer screening

  • An aid to detect cancer progression or relapse

DxPG80.smart is also a confirmatory tool for physicians clinical decision in case the other diagnostic tests give results at the limit of the interpretation. 

DxPG80.smart  should be considered as a clinical decision aid.

2. > Help Follow-up

THE GOAL

An aid to detect cancer progression or relapse. DxPG80.lab is a new tool for patient follow-up. Its goal is to help evaluate a given therapeutic strategy objectively.

Follow-up

of cancer patients

APPROACH

Providing a new tool to help follow up on patients

 

DxPG80.lab is an efficient and inexpensive new tool to help you to monitor treatment efficiency during and after therapy. Simple, reliable, and reproducible, 

DxPG80.lab detects progastrin in a cancer patient’s blood.

2.

A new tool to help physicians to detect multiple cancers susceptibility at early stages

ECS-progastrin has developed the first true test for helping early cancer screening working for multiple cancers and meeting all these criteria. Called DxPG80, this IVD test is able to detect a specific biomarker in the blood: hPG80 (Progastrin).

In almost all types of cancers, at the earliest stages of development, there is an uncontrolled activation of the Wnt oncogenic pathway. This uncontrolled activation of the Wnt oncogenic pathway is vital for the cancer cells to grow and survive. It induces the expression of multiple genes required for the cancer cells to grow and survive. Among these multiple genes, there is the gene coding for our target: Progastrin.

DxPG80 IVD test is CE marqued under  the project name cancerREAD. Regulatory revisions are ongoing.

Simple,

Reliable,

Reproductible 

Solution

 
 
 

Secure your future

IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detect the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved